Articles On Opthea (ASX:OPT)

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoTech winning the race for Best in Show Aruma Resources led the small caps winners   The local benchmark moved strongly into positive terri...

If you have a high tolerance for risk and are looking for big investment returns, then read on. That's because analysts at Bell Potter have just picked out one speculative ASX stock that they believe could rise materially from current level...

The Core Lithium Ltd (ASX: CXO) share price is surging higher today. Shares in the All Ordinaries Index (ASX: XAO) lithium stock closed yesterday trading for 11 cents. In morning trade on Wednesday, shares are swapping hands for 12.5 ce...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday. In afternoon trade, the benchmark index is down 0.25% to 7,998.8 points. Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:...

It has not been an easy time to invest in ASX lithium stocks. Unless you were shorting them, lithium investors are likely to be nursing sizeable paper losses over the last 12 months. During this time, lithium stocks such as Arcadium Lithiu...

The All Ordinaries Index (ASX: XAO) is up 0.8% hitting new all-time highs, and it's getting plenty of support from this soaring ASX All Ords stock. Shares in the investment software provider closed on Friday trading for $1.07. In earlie...

The S&P/ASX 200 Index (ASX: XJO) has started the week strongly on Monday. In afternoon trade, the benchmark index is up 0.9% to 8,030.9 points. Four ASX shares that are rising more than most today are listed below. Here's why they are...

The Nanosonics Ltd (ASX: NAN) share price is having a very strong start to the week. In morning trade, the infection control specialist's shares were up as much as 10% to $3.47. Why is the Nanosonics share price surging 10%? Investors have...

It's that time of year again when investors check their leaders and laggards and potentially rotate into cheap ASX 200 stocks. Analysts have already started the process. Deterra Royalties Ltd (ASX: DRR) has caught Goldman Sachs' attentio...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

It is fair to say that the 2024 financial year was not kind to Core Lithium Ltd (ASX: CXO) shares. During the 12 months, the lithium miner's shares lost approximately 90% of their value. Will things be better for shareholders in the new fin...

Despite the past two days of solid gains, the Core Lithium Ltd (ASX: CXO) share price remains down 35.7% since this time last month. Shares in the All Ordinaries Index (ASX: XAO) lithium stock are currently flat, trading at yesterday's c...

Opthea (ASX:OPT) has announced the completion of the institutional component of the recently announced capital.

The ASX200 is down a third of a per cent to close the week. All sectors were in the red, except Consumer Discretionary stocks which pushed ahead, and, healthcare also made gains. In the Green And with the rise in Consumer Discretio...

It was another disappointing session for the Core Lithium Ltd (ASX: CXO) share price. During Friday's trade, the lithium miner's shares tumbled to a new multi-year low of 9 cents. And while it ended the day a fraction higher at 9.2 cents, t...

ASX200 dropped on Friday, extending its weekly loss despite Wall Street’s highs Telix Pharma halted US IPO; Tabcorp jumps 10pc on NSW tax reform Germany works to soften EU tariffs on Chinese electric cars   The ASX200 dropped by -0.3% on...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued finish to the week. In afternoon trade, the benchmark index is down 0.3% to 7,728.6 points. Four ASX shares that are falling more than most today are listed below. Here's why they a...

As the S&P/ASX 200 Index (ASX: XJO) slips around 0.3% into the red on Friday, one ASX 200 stock has copped a hammering. Deterra Royalties Ltd (ASX: DRR) shares took a significant hit at the open and were down 10% in early trade. Howe...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Australian company Opthea (ASX:OPT) has announced it is seeking to raise approximately $227.3 million to advance the late-stage development of OPT-302 (sozinibercept), a drug for progressive retinal diseases, including wet age-relat...

ASX down 0.5pc, Energy sector up due mainly to Woodside’s upgrade. CRH to acquire Adbri, ending Adbri’s 62-year ASX presence China’s data CPI keeps increasing, new data shows   The ASX continued yesterday’s decline, down another -0.5% tod...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

PainChek granted patent in Europe PainChek (ASX:PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent was given for the PainChek app, an AI platform designed to analyse facial expressions, voc...

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Cheap ASX shares are capable of paying very high dividend yields because of their cheap valuation. Assuming a dividend cut isn't coming, a big potential yield can be very appealing because of how much it can contribute to total sharehold...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

A2 Milk Company Ltd (ASX: A2M) shares are on form and rising nicely on Tuesday. At the time of writing, the infant formula company's shares are up almost 2% to $5.86. Why are A2 Milk shares rising? Investors may have been buying the company...

Much to the relief of Aussie investors, the S&P/ASX 200 Index (ASX: XJO) is having a much better session on Thursday. In afternoon trade, the benchmark index is up 0.5% to 7,819.2 points. Four ASX shares that have failed to follow the...

“It’s a privilege to join the Board of Opthea at such a transformative time,” said Sujal Shah. “I look forward to partnering with the executive leadership team and the Board as we continue to drive sozinibercept forward, with the go...

Opthea look to transform standard of care treatment for wet AMD to improve vision outcomes Two Phase 3 trials are underway investigating lead drug OPT-302 with results from both forecast mid 2025 Opthea looking to be first drug statistical...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Clarity says initial data from Phase 1/2 trial is positive Opthea completes enrolment of all patients in the COAST Phase 3 trial ProMedicus locks in record half   Clarity’s Phase 1/2 trial shows positive initial results Clarity Pharmaceut...

Opthea (ASX:OPT) has announced that it has completed the enrolment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept in combination with aflibercept.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Opthea (ASX:OPT) has announced that CEO Dr Megan Baldwin will transition to founder and chief innovation officer, appointing US-based executives Dr Frederic Guerard as CEO and Peter Lang as chief financial officer.

Benchmark ASX index closes short by -0.04% Materials sector tries but cannot offset everyone else  Small caps led by HAL, DTC   The ASX200 Index has closed slightly lower after jumping early (+0.3%) out the gates on Wednesday morning. The...

Broker Rating Changes (PostThursday Last Week) Upgrade AMA GROUP LIMITED ((AMA)) Upgrade to Buy from Speculative Buy by Canaccord Genuity.B/H/S: 0/0/0 Having recently completed a $55m capital raise,AMA Group is set to deploy $35mto repay se...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX 200 benchmark rises almost 0.6% Tech Sector recovers Wednesday’s losses, after Nasdaq positivity  Miners lead small cap gains, ERW, RDN, AZS winning at home in Andover South   The Australian share market was up and about early on Thur...

Melbourne-headquartered biotech company Opthea (ASX: OPT) has kicked off an $80 million capital raise to support clinical development of its drug candidate aimed at treating wet AMD (age-related macular degeneration), the most common cause...

The private equity giant has signalled its intention to take up an option to invest another $80 million in the clinical-stage biotech